Dry powder inhalers for optimal drug delivery

Bibliography

• NEWMAN SP BUSSE WW: Evolution ofdry powder inhaler design, formulation and performance. Respir. Med. (2002) 96:293–304.
   PubMed Web of Science ®Google Scholar
• •Review of factors affecting drug delivery from powder inhalers.
   Google Scholar
• TAPLIN GV, COHEN SH,MAHONEY EB: Prevention of postoperative pulmonary infections. JAMA (1948) 138:4–8.
   PubMed Web of Science ®Google Scholar
• THIEL CG: From Susie&s question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Respiratory Drug Delivery VDalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1996):115–123.
   Google Scholar
• MCDONALD KJ, MARTIN GP: Transition to CFC-free metered dose inhalers: into the new millennium. Lit. j Pharm. (2000) 211:89–107.
   Google Scholar
• CROMPTON GK: Problems patients have using pressurised aerosol inhalers. Eur Respir. Dis. (1982) 63\(Suppl. 119):57–65.
   Google Scholar
• CLARK AR: Medical aerosol inhalers: past, present and future. Aerosol Sci. Technol (1995) 22:374–391.
   Web of Science ®Google Scholar
• •Summary of DPI present and future technology as of 1995.
   Google Scholar
• PARTRIDGE MR, WOODCOCK AA, SHEFFER AL, WANNER A,RUBINFELD A: Chlorofluorocarbon-free inhalers: are we ready for the change? Eur. Respic (1998) 11:1006–1008.
   Google Scholar
• LEACH CL, DAVIDSON PJ,BOUDREAU RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. (1998) 12:1346–1353.
   PubMed Web of Science ®Google Scholar
• SMITH U, PARRY-BILLINGS M: The inhalers of the future? A review of dry powderdevices on the market today. Palm. Phannacol Therapeut. (2003) 16:79–95.
   PubMed Web of Science ®Google Scholar
• ••Up-to-date detailed review of currently marketed DPIs.
   Google Scholar
• SMART JR: A brief overview of novel liquid-based inhalation technologies. Drug Deily. Syst. Sci. (2002) 2:67–71.
   Google Scholar
• PARRY-BILLINGS M: Dry powder inhalers: an expanding field. Eric Pharm. Contractor (2001) February:42–49.
   Google Scholar
• •Useful summary of current DPI technology.
   Google Scholar
• HOCHRAINER D, SPALLEK M: Handihaler: a new powder inhaler for COPD treatment. Proceedings of Drug Delivery to the Lungs XIII The Aerosol Socieor, Bristol, UK (2002):140–143.
   Google Scholar
• WETTERLIN K: Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res. (1988) 5:506–508.
   PubMed Web of Science ®Google Scholar
• YANG TT, KENYON D: Use of an agglomerate formulation in a new multidose dry powder inhaler. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):503–505.
   Google Scholar
• BRAIN JD, BLANCHARD JD: Mechanisms of particle deposition and clearance. In: Aerosols in Medicine: principles, diagnosis and therapy Morén F, Dolovich MB, Newhouse MT, Newman SP (Eds), Elsevier, Amsterdam, The Netherlands (1993):117–156.
   Google Scholar
• CLARK AR, HOLLINGWORTH A: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in-vitro testing. I Aerosol Med. (1993) 6:99–110.
   PubMedGoogle Scholar
• CHAVAN V, DALBY R: Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler. AAPS PharmSci. (2002) 4(2):E2.
   PubMedGoogle Scholar
• LALLOO U: Symbicort: controlling asthma in adults. Respic Med. (2002) 96(Suppl. A):516–522.
   Google Scholar
• THORSSON L, EDSBACKER S, CONRADSON T-B: Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur. Respic (1994) 7:1839–1844.
   PubMed Web of Science ®Google Scholar
• THORSSON L, KENYON CJ, NEWMAN SP, BORGSTROM L: Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int.' Pharm. (1998) 168:119–127.
   Web of Science ®Google Scholar
• BORGSTROM L, BONDESSON E, MORN F, TROFAST E, NEWMAN SP: Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eric Respic (1994) 7:69–73.
   PubMed Web of Science ®Google Scholar
• BISGAARD H: Automatic actuation of a dry powder inhaler into a non-electrostatic spacer. Am.j Respic Crit. Care Med. (1998) 157:518–521.
   PubMed Web of Science ®Google Scholar
• BRINDLEY A, SUMBY BS, SMITH IJ, HAYWOOD PA, GRANT AC: Design, manufacture and dose consistency of the Serevent Diskus Inhaler. Pharm. Tech. Eric (1995) 9:14–22.
   Google Scholar
• JOHNSON M: Fluticasone propionate: pharmacokinetic and pharmacodynamic implications of different aerosol delivery systems. In: Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1998):61–70.
   Google Scholar
• ASKING L, AXELSON M, LINDBERG J: Aluminium blisters may fail to protect against humidity. Proceedings of Drug Delivery to the Lung IX. The Aerosol Society Bristol, UK (1998):84–87.
   Google Scholar
• SUMBY BS, CHURCHER KM,SMITH IJ et al.: Dose reliability of the Serevent Diskhaler system. Pharm. Tech. Int. (1993) June:20–27.
   Google Scholar
• CASS LMR, BROWN J, PICKFORD M et al.: Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin. Pharmacokinet. (1999) 36\(Suppl. 1):21–31.
   Google Scholar
• PARRY-BILLINGS M, BOYES RN, CLISBY LM, BRAITHWAITE P, WILLIAMS S, HARPER AE: Design, development and performance of a multidose dry powder inhaler. Pharm. Tech. (2000) February:38–45.
   Google Scholar
• SANDERS MJ: Divide and conquer: a new approach to delivery of inhaled combination therapies. Drug Delivery Companies Report (2003) Spring/Summer:14–18.
   Google Scholar
• YANG TT, WYKA B, KENYON D: Drug delivery performance of the mometasone furoate dry powder inhaler. Aerosol Med. (2001) 14:487–494.
   PubMedGoogle Scholar
• FYRNYS B, STANG N, WOLF-HEUSS E: Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder device. Curt: Opin. Palm. Med. (2001) 7\(Suppl. 1):57–S11.
   Google Scholar
• NEWMAN SP, PITCAIRN GR,HIRST PH et al.: Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Ear: Respic (2000) 16:178–183.
   Google Scholar
• KUNKEL G, CHUCHALIN AG: Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma. Carr: Opin. Palm. Med. (2001) 7\(Suppl. 1):515–517.
   Google Scholar
• NEWMAN SP, MALIK S, HIRST PH et al.: Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. Respic Med. (2002) 96:1026–1032.
   PubMed Web of Science ®Google Scholar
• PITCAIRN GR, LIM J,HOLLINGWORTH A, NEWMAN SP: Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. .1. Aerosol Med. (1997) 10:295–306.
   Google Scholar
• KEATING GM, FAULDS D: Airmax: a multi-dose dry powder inhaler. Drugs (2002) 62:1887–1897.
   PubMed Web of Science ®Google Scholar
• HIRST PH, NEWMAN SP, CLARK DA, HERTOG MGL: Lung deposition of budesonide from the novel dry powder inhaler Airmax. Respic Med. (2002) 96:389–396.
   PubMed Web of Science ®Google Scholar
• PITCAIRN GR, LANKINEN T, SEPPALA O-P, NEWMAN SP: Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of thepatient's inspiratory effort. Aerosol Med. (2000) 13:97–104.
   PubMedGoogle Scholar
• STECKEL H, RASENACK N, VILLAX P, MULLER BW: Delivery of engineered particles using a new capsule-based inhaler. Proceedings of Drug Delivery to the Lungs XIII, The Aerosol Society Bristol, UK (2002):184–187.
   Google Scholar
• VILLAX P, BRITO V, STECKEL H: Development and performance of a new simple dry powder inhaler operating at low airflow rates. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SF (Eds), Davis Horwood, Raleigh, NC, USA (2002):459–462.
   Google Scholar
• NILSSON T: Creating a high performance and patient-orientated inhaler for the treatment of asthma and COPD. Presentation to Management Forum Conference, Frankfurt (2003) July.
   Google Scholar
• KELDMANN T: The DirectHaler. Presentation to Management Forum Conference, London (2003) June.
   Google Scholar
• BORGSTROM L: On the use of dry powder inhalers in situations perceived as constrained. Aerosol Med. (2001) 14:281–287.
   PubMedGoogle Scholar
• HILL M, VAUGHAN L, DOLOVICH M: Dose targeting for dry powder inhalers. In: Respiratory Drug Delivery V Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1996):197–208.
   Google Scholar
• DOLOVICH M, RHEM R, RASHID F, COATES G, HILL M, BOWEN B: Measurement of the particle size and dosing characteristics of a radiolabelled albuterol sulphate lactose blend used in the Spiros dry powder inhaler. In: Respiratory Drug Delivery V Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1996):332–336.
   Google Scholar
• PATTON JS: Deep-lung delivery of therapeutic proteins. Chemtech (1997) December:34–38.
   Google Scholar
• PATTON JS, BUKAR J, NAGARAJAN S: Inhaled insulin. Adv. Drug Deify. Rev (1999) 35:235–247.
   PubMed Web of Science ®Google Scholar
• CLARK AR: Formulation of proteins and peptides for inhalation. Drug Deify. Syst. Sci. (2002) 2:73–77.
   Google Scholar
• •Discusses how novel formulation strategies can be used to optimise drug delivery from DPIs.
   Google Scholar
• WHELAN J: Electronic DPI for insulin. Drug Discov. Today (2002) 7:213–214.
   PubMed Web of Science ®Google Scholar
• SCHULTZ RK, MILLER NC, SMITH DK, ROSS DL: Powder aerosolswith auxiliary means of dispersion. Biopharm. ScL (1992) 3:115–121.
   Google Scholar
• HODSON D: A tape-based pre-metered DPI. Presentation to Management Forum conference, London (2003) June.
   Google Scholar
• BOEKESTEIN VJ, HICKEY AJ, CROWDER TM: Uniform and reproducible delivery of albuterol from a variety of lactose powder blends using the Oriel active dispersion platform. Proceedings of Drug Delivery to the Lungs XIII, The Aerosol Society Bristol, UK (2002) :107–110.
   Google Scholar
• YOUNG PM, THOMPSON J, PRICE R, WOODCOCK D, DAVIES K: The use of a novel 'active' inhalation device to deliver high respirable fractions of high dose dry powder active agents to the lung. Aerosol Med. (2003) 16:192 [Abstract].
   Google Scholar
• TIMSINA MP, MARTIN GP, MARRIOTT C, GANDERTON D, YIANNESKIS M: Drug delivery to the respiratory tract using dry powder inhalers. hat. Pharm. (1994) 101:1–13.
   Google Scholar
• STANIFORTH JN, BRAITHWAITE P, GANDERTON D et al.: Advanced pulmonary systems: a novel high performance formulation-integrated dry powder inhaler for peptide and protein systemic drug delivery. Proceedings of Drug Delivery to the Lungs XII, The Aerosol Society Bristol, UK (2001):70–73.
   Google Scholar
• STANIFORTH JN, PATEL N,MORTON DAV et al.: Biotech-DPI strategies: accomplishing affordable control and affective action. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, PeartJ, Farr SF (Eds), Davis Horwood, Raleigh, NC, USA (2002):267–276.
   Google Scholar
• •Detailed discussion of one novel approach for powder formulation.
   Google Scholar
• OSTRANDER KD, HOVEY DC, KNAPP DA, PARRY-BILLINGS M: Potential delivery advantages of spray-dried nanocrystal colloidal budesonide with the Clickhaler. In: Respiratory Drug Delivery VII Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000)447–449.
   Google Scholar
• EDWARDS DA, HANES J,CAPONETTI G et al: Large porous particles for pulmonary drug delivery. Science (1997) 276:1868–1871.
   PubMed Web of Science ®Google Scholar
• ••First paper describing the use ofengineered powder particles for pulmonary delivery.
   Google Scholar
• EDWARDS DA, CHEN D, WANG J, BEN-JEBRIA A: Controlled release inhalation aerosols. In: Respiratory Drug Delivery VI Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1998):186–192.
   Google Scholar
• TARARA TE, WEERS J, DELLAMARY L: Engineered powders for inhalation. In: Respiratory Drug Delivery VII Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):413–416.
   Google Scholar
• YORK P: Strategies for particle design using supercritical fluid technologies. Pharm. Sci. 7echnol. Today (1999) 2:430–440.
   PubMedGoogle Scholar
• YORK P: The challenges of drug delivery. Drug Deify. Sci. Syst. (2002) 2:57–59.
   Google Scholar
• BLAIR J, MAO L, HODGERS E: Modification of the pulmonary absorption of cyclosporin using SoliDose technology. In: Respiratory Drug Deli very VH.Dalby RN, Byron PR, Farr SJ, PeartJ (Eds), Serentec Press, Raleigh, NC, USA (2000)481–483.
   Google Scholar
• WILSON BR, GRANT MI, STEINER SS, POHL R: Technospheres for pulmonary and nasal applications. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, PeartJ, Farr SF (Eds), Davis Horwood, Raleigh, NC, USA (2002):545–548.
   Google Scholar
• BROWN LR, RASHBA-STEP J, SCOTT T et al.: Pulmonary delivery of novel insulin microspheres. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SF (Eds), Davis Horwood, Raleigh, NC, USA (2002):431–434.
   Google Scholar
• DUNBAR C: Dry powder formulations for inhalation. Drug Deify. Syst. Sci. (2002) 2:78–80.
   Google Scholar
• GANDERTON DJ, KASSEM NM: Dry powder inhalers. In: Advances in Pharmaceutical Sciences. Ganderton DJ, Jones T (Eds), Academic Press, London (1992):165–191.
   Google Scholar
• ••Contains text-book data about theformulation factors affecting dry powder delivery.
   Google Scholar
• ZENG XM, MARTIN GP,MARRIOTT C, PRITCHARD J: The influence of carrier morphology on drug delivery by dry powder inhalers. hat. Pharm. (2000) 200:93–106.
   Google Scholar
• WARREN S, TAYLOR G, GODFREY C et al.: Budesonide Clickhaler formulation development: does in vitro aerosol performance predict in vivo lung delivery? Proceedings of Drug Delivery to the Lungs X, The Aerosol Socien", Bristol UK (1999):160–162.
   Google Scholar
• YAMASHITA C, IBARAGI S: A novel dry powder inhalation system for proteins and peptides. Aerosol Med. (2003) 16:209 [Abstract].
   Google Scholar
• MUELLER-WALZ R, FUEG L-M, GILCHRIST P, LEFRANCOISE G, NIEDERLANDER C: Skye Protect: a novel approach to improved stability of dry powders for inhalation.' Aerosol Med. (2001) 14:120 [Abstract].
   Google Scholar
• WEERS J: Dispersible powders for inhalation applications. Innovations Pharmaceut. Technol (2001) June:111–116.
   Google Scholar
• ASHURST I, MALTON A, PRIME D, SUMBY B: Latest advances in the development of dry powder inhalers. Pharm. Sci. 7echnol. Today (2000) 3:246–256.
   PubMedGoogle Scholar
• •Good summary of recent device and formulation technology.
   Google Scholar
• PEART J, CLARKE MJ: New developments in dry powder inhaler technology. Am. Pharm. Rev (2001) October:27–45.
   Google Scholar
• ••Very good summary of novel dry powderformulation approaches.
   Google Scholar
• DUNBAR C, SCHEUCH G, SOMMERER K, DELONG M, VERMA A, BATYCKY R: In vitro and in vivo dose delivery characteristics of largeporous particles for inhalation. Int. Pharm. (2002) 245:179–189.
   PubMed Web of Science ®Google Scholar
• DE LONG M, DAWSON M, MEYER T, SOMMERER K, DUNBAR C: In vivo dose delivery characteristics of the AIR pulmonary delivery system over a wide range of inspiratory flow rates. Aerosol Med. (2003) 16:188 [Abstract].
   Google Scholar
• DUDDU SP, SISK SA, WALTER YH et al.:Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm. Res. (2002) 19:689–695.
   PubMed Web of Science ®Google Scholar
• •Describes how lung deposition may be optimised using one type of engineered powder.
   Google Scholar
• NEWHOUSE MT, HIRST PH, DUDDU SP et al.: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest (2003) 124(1):360–366.
   PubMed Web of Science ®Google Scholar
• http://www.vectura.co.uld technology_platforms/aspirair.html Vectura website (2003).
   Google Scholar